–
Статьи в журналах
-
- 2021 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
- Sahin1 U., 2, 3, Türeci3, 4, Manikhas5 G., Lordick6 F., Rusyn7 A., Vynnychenko8 I., Dudov9 A., Bazin I., Bondarenko11 I., Melichar12 B., Dhaene13 K., Wiechen14 K., Huber1 C., 3, 4, Maurus15 D., Arozullah16 A., Park16 J.W., Schuler17y M., Al-Batran18* S.E.
- в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 5, с. 609-619 DOI